Alteral Therapeutics ApS: Financial statements 2025
CVR: 43730967
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Alteral Therapeutics ApS (CVR 43730967) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -125,267 and a net result of DKK 624,026 compared with DKK 20,137 the year before. Equity in the 2025 report amounted to DKK 978,560. The solvency ratio was 93.9%.
- Gross Profit
- DKK -125,267
- Profit/Loss
- DKK 624,026
- Equity
- DKK 978,560
- Total Assets
- DKK 1,042,112
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -125K | 624K | 979K | 0 |
| 2024 | - | - | 20K | 355K | - |
| 2023 | - | - | 294K | 334K | - |
Official annual report
How creditworthy is Alteral Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Alteral Therapeutics ApS has published its annual report for 2024. The net result was DKK 20,137.
About Alteral Therapeutics ApS
Alteral Therapeutics ApS is a Danish company of the type Anpartsselskab based in Allerød, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Allan Traugott Wehnert. The company is owned by Wehnert Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -125,267 and a net result of DKK 624,026 compared with DKK 20,137 the year before. Equity in the 2025 report amounted to DKK 978,560.